Towards Healthcare
Sex-Based Drug Development Market Trends and Key Players by 2034

Sex-Based Drug Development Market Overlooked Variable in Clinical Research

Around the world, the sex-based drug development market is driven by the rising approaches to sex-based differences, like pharmacokinetic, pharmacodynamic, and hormonal characteristics. Whereas, North America dominated the global market, with a growing number of research activities and an increasing focus on personalized approaches in drug development. 

Content

  • Insight Code: 5738
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: June 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

Sex-based drug development is on the rise, driven by demand for gender-specific treatments and precision medicine from 2024 to 2034.

North America is currently leading the sex-based drug development market due to rising research activities related to sex-specific approaches and increasing focus on personalized medicine.

The sex-based drug development market includes 6 segments, such as by gender, by drug type, by disease, by route of administration, by distribution channel, and by region, etc.

Some key players include Pfizer, Reckitt Benckiser Group PLC, Roche, and Novartis.

Key trends include rising demand for drug discovery and personalized medicine, growth in programs related to womens health, and innovation in clinical trials, novel molecules.

The significance of sex-based drug development arises from the basic biological differences between males and females, including pharmacokinetic, pharmacodynamic, and hormonal differences.

Raising research activities and clinical trials with diverse participation can improve sex-based drug development.

US FDA.GOV, NIH.GOV, FEDERAL REGISTER.GOIV, BBC, PIB.GOV, CDC.GOV
Any Questions